{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:57:36Z","timestamp":1791219456545,"version":"4.1.0"},"reference-count":48,"publisher":"Japanese Society of Hypertension","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2005]]},"DOI":"10.1291\/hypres.28.787","type":"journal-article","created":{"date-parts":[[2006,5,12]],"date-time":"2006-05-12T08:03:27Z","timestamp":1147421007000},"page":"787-795","source":"Crossref","is-referenced-by-count":55,"title":["Impact of the Angiotensin II Receptor Antagonist, Losartan, on Myocardial Fibrosis in Patients with End-Stage Renal Disease: Assessment by Ultrasonic Integrated Backscatter and Biochemical Markers"],"prefix":"10.1291","volume":"28","author":[{"given":"Yasunobu","family":"SHIBASAKI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"NISHIUE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"MASAKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"TAMURA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"MATSUMOTO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasukiyo","family":"MORI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsushige","family":"NISHIKAWA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"MATSUBARA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiji","family":"IWASAKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Shinzato T, Nakai S, Akiba T, <i>et al<\/i>: Report of the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996. <i>Kidney Int<\/i> 1999; <b>55<\/b>: 700-712.","DOI":"10.1046\/j.1523-1755.1999.00297.x"},{"key":"2","unstructured":"2. Geerling W, Tufveson G, Broyer M, Brunner FP, Brynger H, Fassbinder W: Combined report on regular dialysis and transplantation in Europe. <i>Proc Eur Dial Transplant Assoc<\/i> 1983; <b>17<\/b>: 52-54."},{"key":"3","unstructured":"3. Amann K, Tyralla K: Cardiovascular changes in chronic renal failure&mdash;pathogenesis and therapy. <i>Clin Nephrol<\/i> 2002; <b>58<\/b> (Suppl 1): S62-S72."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Matsubara H: Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. <i>Circ Res<\/i> 1998; <b>83<\/b>: 1182-1191.","DOI":"10.1161\/01.RES.83.12.1182"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sadoshima J, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. <i>Circ Res<\/i> 1993; <b>73<\/b>: 413-423.","DOI":"10.1161\/01.RES.73.3.413"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1007\/BF00226785"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Dostal DE: Regulation of cardiac collagen: angiotensin and cross-talk with rocal growth factors. <i>Hypertension<\/i> 2001; <b>37<\/b>: 841-844.","DOI":"10.1161\/01.HYP.37.3.841"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lattanzi F, Bello VD, Picano E, <i>et al<\/i>: Normal ultrasonic myocardial reflectivity in athletes with increased left ventricular mass: a tissue characterization study. <i>Circulation<\/i> 1992; <b>85<\/b>: 1828-1834.","DOI":"10.1161\/01.CIR.85.5.1828"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J: Biochemical assessment of myocardial fibrosis in hypertensive heart disease. <i>Hypertension<\/i> 2001; <b>38<\/b>: 1222-1226.","DOI":"10.1161\/hy1101.098549"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Diez J, Laviades C: Monitoring fibrillar collagen turnover in hypertensive heart disease. <i>Cardiovasc Res<\/i> 1997; <b>35<\/b>: 202-205.","DOI":"10.1016\/S0008-6363(97)00072-2"},{"key":"11","unstructured":"11. Shibasaki Y, Mori Y, Tsutsumi Y, <i>et al<\/i>: Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. <i>Clin Nephrol<\/i> 1999; <b>51<\/b>: 83-91."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sahn DJ, Demaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of survey of echocardiographic measurements. <i>Circulation<\/i> 1978; <b>58<\/b>: 1072-1083.","DOI":"10.1161\/01.CIR.58.6.1072"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Schiller NB, Shah PM, Crawford M, <i>et al<\/i>: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. <i>J Am Soc Echocardiogr<\/i> 1989; <b>2<\/b>: 358-367.","DOI":"10.1016\/S0894-7317(89)80014-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Harnett JD, Murphy B, Collingwood P, Purchase L, Kent G, Parfrey PS: The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. <i>Nephron<\/i> 1993; <b>65<\/b>: 212-214.","DOI":"10.1159\/000187476"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ando Y, Yanagiba S, Asano Y: The inferior vena cava diameter as a marker of dry weight in chronic hemodialyzed patients. <i>Artif Organs<\/i> 1995; <b>19<\/b>: 1237-1242.","DOI":"10.1111\/j.1525-1594.1995.tb02292.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Langendorf R, Pirani CL: The heart in uremia. <i>Am Heart J<\/i> 1947; <b>33<\/b>: 282-307.","DOI":"10.1016\/0002-8703(47)90657-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Amann K, Ritz E, Wiest G, Klaus G, Mall G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. <i>J Am Soc Nephrol<\/i> 1994; <b>10<\/b>: 1814-1819.","DOI":"10.1681\/ASN.V4101814"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wickline SA, Thomas LJ III, Miller JG, <i>et al<\/i>: The dependence of myocardial ultrasonic integrated backscatter on contractile performance. <i>Circulation<\/i> 1985; <b>72<\/b>: 183-192.","DOI":"10.1161\/01.CIR.72.1.183"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Picano E, Pelosi G, Marzilli M, <i>et al<\/i>: <i>In vivo<\/i> quantitative ultrasonic evaluation of myocardial fibrosis in humans. <i>Circulation<\/i> 1990; <b>81<\/b>: 58-64.","DOI":"10.1161\/01.CIR.81.1.58"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. O'Brien PD, O'Brien WD, Rhyne TL, <i>et al<\/i>: Relation of ultrasonic backscatter and acoustic propagation of myofibrillar length and myocardial thickness. <i>Circulation<\/i> 1995; <b>91<\/b>: 171-175.","DOI":"10.1161\/01.CIR.91.1.171"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)91002-2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wickline SA, Verdonk ED, Wong AK, <i>et al<\/i>: Structural remodeling of human myocardial tissue after infarction: quantification with ultrasonic backsatter. <i>Circulation<\/i> 1992; <b>85<\/b>: 259-268.","DOI":"10.1161\/01.CIR.85.1.259"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mimbs JW, O'Donnel M, Bauwens D, <i>et al<\/i>: The dependence of ultrasonic attenuation and backscatter on collagen content in dog and rabbit hearts. <i>Circ Res<\/i> 1980; <b>47<\/b>: 48-58.","DOI":"10.1161\/01.RES.47.1.49"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sagar KB, Rhyne TL, Waltier DC, <i>et al<\/i>: Intramyocardial variability in integrated backscatter: effects of coronary occlusion and reperfusion. <i>Circulation<\/i> 1987; <b>75<\/b>: 436-442.","DOI":"10.1161\/01.CIR.75.2.436"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Nozaki S, DeMaria AN, Helmer GA, <i>et al<\/i>: Detection of regional left ventricular dysfunction in early pacing-induced heart failure using ultrasonic integrated backscatter. <i>Circulation<\/i> 1995; <b>92<\/b>: 2676-2682.","DOI":"10.1161\/01.CIR.92.9.2676"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Masuyama T, Goar FG, Tye TL, <i>et al<\/i>: Ultrasonic tissue characterization of human hypertrophied hearts <i>in vivo<\/i> with cardiac cycle-dependent variation in integrated backscatter. <i>Circulation<\/i> 1989; <b>80<\/b>: 925-934.","DOI":"10.1161\/01.CIR.80.4.925"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Feinberg MS, Gussak HM, Davila-Roman VG, <i>et al<\/i>: Dissociation between wall thickening of normal myocardium and cyclic variation of backscatter during inotropic stimulation. <i>Am J Cardiol<\/i> 1996; <b>77<\/b>: 515-520.","DOI":"10.1016\/S0002-9149(97)89347-2"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000017264.66561.3D"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Laurent GJ: Dynamic state of collagen: pathways of collagen degradation <i>in vivo<\/i> and their possible role in regulation of collagen mass. <i>Am J Physiol<\/i> <b>251<\/b>: C1-C9, 1987.","DOI":"10.1152\/ajpcell.1987.252.1.C1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Laragh JH: Renin profiling for diagnosis, risk assessment, and treatment of hypertension. <i>Kidney Int<\/i> 1993; <b>44<\/b>: 1163-1175.","DOI":"10.1038\/ki.1993.363"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Suzuki J, Matsubara H, Inada M: Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. <i>Circ Res<\/i> 1993; <b>73<\/b>: 439-447.","DOI":"10.1161\/01.RES.73.3.439"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kijima K, Matsubara H, Murasawa S, <i>et al<\/i>: Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. <i>Circ Res<\/i> 1996; <b>79<\/b>: 887-897.","DOI":"10.1161\/01.RES.79.4.887"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A: Angiotensin II-forming pathways in normal and failing human hearts. <i>Circ Res<\/i> 1990; <b>66<\/b>: 883-890.","DOI":"10.1161\/01.RES.66.4.883"},{"key":"34","unstructured":"34. Himmelmann A, Svensson A, Bergbrant A, Hansson L: Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. <i>J Hum Hypertens<\/i> 1996; <b>10<\/b>: 729-734."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Role of anemia in pathogenesis of left ventricular hypertrophy in end-stage renal disease. <i>Am J Cardiol<\/i> 1989; <b>64<\/b>: 222-224.","DOI":"10.1016\/0002-9149(89)90462-1"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Martinez-Vea A, Bardaji A, Garcia C, Ridao C, Richart C, Oliver JA: Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. <i>Am J Kidney Dis<\/i> 1992; <b>19<\/b>: 353-357.","DOI":"10.1016\/S0272-6386(12)80453-7"},{"key":"37","unstructured":"37. Washio M, Okuda S, Mizoue T, <i>et al<\/i>: Risk factors for left ventricular hypertrophy in chronic hemodialysis patients. <i>Clin Nephrol<\/i> 1997; <b>47<\/b>: 362-366."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. London GM, De Vernejoul MC, Fabiani F, <i>et al<\/i>: Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. <i>Kidney Int<\/i> 1987; <b>32<\/b>: 900-907.","DOI":"10.1038\/ki.1987.293"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00484.x"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.227"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.835"},{"issue":"3","key":"42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/01.HYP.22.3.339","volume":"22","year":"1993","ISSN":"https:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Burnier M, Roch-Ramel F, Brunner HR, <i>et al<\/i>: Renal effects of angiotensin II receptor blockade in normotensive subjects. <i>Kidney Int<\/i> 1996; <b>49<\/b>: 1787-1790.","DOI":"10.1038\/ki.1996.268"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Ganau A, Devereux RB, Roman MJ, <i>et al<\/i>: Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. <i>J Am Coll Cardiol<\/i> 1992; <b>19<\/b>: 1550-1508.","DOI":"10.1016\/0735-1097(92)90617-V"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Cannella G, Paoletti E, Delfino R, <i>et al<\/i>: Regression of left ventricular hypertrophy on hypertensive dialyzed uremic patients on long-term antihypertensive therapy. <i>Kidney Int<\/i> 1993; <b>44<\/b>: 881-886.","DOI":"10.1038\/ki.1993.326"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.25.191"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.24.601"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.26.945"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T04:16:38Z","timestamp":1627359398000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nature.com\/doifinder\/10.1291\/hypres.28.787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1291\/hypres.28.787","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}